-0.63 | -12.02%
| Price and Volume | |
|---|---|
| Recent Price | 5.24 |
| 52 Week High | 24.30 |
| 52 Week Low | 2.66 |
| Avg. Daily Vol. (Mil) | 0.03 |
| Beta (3 year) | 0.73 |
| Share Related Items | |
| Mkt Cap (Mil) | 9.52 |
| Shares Out (Mil) | 1.82 |
| Float (Mil) | 1.41 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.70 |
| Current Ratio | 4.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 1.52 |
| Price/Cash Flow | -0.90 |
| Per Share Data | |
| Earnings | -5.75 |
| Sales | 0.00 |
| Book Value | 3.45 |
| Cash Flow | -5.85 |
| Business Summary | |
|---|---|
| Telik, Inc, is a clinical-stage drug development company, which is focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. | |
| General Information | |
| 700 Hansen Way
Palo Alto, CA 94304 |
|
| www.telik.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 22 | |
| CEO: Dr. Michael M. Wick,M.D. | |
| Short Interest | |
| Current Month (Mil) | 0.02 |
| Previous Month (Mil) | 0.02 |
| Short Interest Ratio (Days) | 2.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -108.10 |
| Return on Investments | -169.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,433.86 | 1,312.76 | 2,842.46 | 16.25 |
Oil *
103.33
|
|
DOWN
146.83 |
DOWN
19.66 |
DOWN
28.53 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.17%
|
-1.48%
|
-0.99%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet